Novavax, Inc.

Novavax to Host Conference Call to Discuss First Quarter Financial Results on May 7, 2015

Novavax to Present at the 14th Annual Needham Healthcare Conference

Novavax Announces Closing of Public Offering

Novavax Presents New Data From Non-Human Primate Ebola Challenge at the 7th International Symposium on Filoviruses

Novavax Prices Public Offering of Common Stock

Novavax Announces Proposed Public Offering of Common Stock

Novavax Appoints Brian Rosen as Vice President, Government Affairs

Novavax Reports Fourth Quarter and Year-End 2014 Financial Results

Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2014 Financial Results on February 26, 2015

Novavax Announces Initiation of Ebola Vaccine Phase 1 Clinical Trial Supported by Non-Human Primate Challenge Data and Documented Rapid Manufacturing Capabilities

Novavax Announces Management Promotion

Novavax to Present at the 33rd Annual J.P. Morgan Healthcare Conference

Novavax to Present at the 26th Annual Piper Jaffray Healthcare Conference

U.S. FDA Grants Fast Track Designation to Novavax’ RSV F-Protein Nanoparticle Vaccine for Protection of Infants Via Maternal Immunization

Novavax Initiates Phase 2 Clinical Trial of Quadrivalent Seasonal Influenza VLP

Novavax to Present at the Jefferies Global Healthcare Conference

Novavax Initiates Phase 1 Clinical Trial of RSV F Vaccine in Pediatric Subjects

Novavax and Collaborators Make Multiple Presentations at the 9th International Respiratory Syncytial Virus Symposium in South Africa, November 9-13, 2014

Novavax Reports Third Quarter 2014 Financial Results

Novavax to Host Conference Call to Discuss Third Quarter 2014 Financial Results on November 5, 2014

U.S. FDA Grants Fast Track Designation to Novavax’ H7N9 Influenza Virus-Like Particle Vaccine Candidate Adjuvanted With Matrix-M(TM)

Novavax Announces Ebola Vaccine Development Program at the 8th Vaccine and ISV Conference in Philadelphia

Novavax Presents RSV F Protein Nanoparticle Vaccine Clinical Data at the 8th Vaccine & ISV Congress in Philadelphia on Sunday, October 26

Novavax to Present RSV Vaccine Clinical Data at the 8th Vaccine & ISV Congress in Philadelphia on Sunday, October 26

Novavax Study Published in Vaccine: RSV F-Protein Nanoparticle Vaccine Induces Antigenic Site II Antibodies

Novavax Initiates Phase 2 Clinical Trial of RSV Vaccine in Elderly Subjects

Novavax Announces BARDA Exercise of Contract Option

Novavax’ H7N9 Avian Influenza VLP Vaccine Candidate With Matrix-M(TM) Delivers Positive Phase 1/2 Clinical Data

Novavax Initiates Phase 2 Clinical Trial of RSV F-Protein Nanoparticle Vaccine Candidate in Healthy Third-Trimester Pregnant Women

Novavax Initiates Phase 2 Clinical Trial of RSV F-Protein Nanoparticle Vaccine Candidate in Healthy Third-Trimester Pregnant Women